Danaher Corporation logo

Danaher Corporation(DHR)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
Consider higher Upturn Star rating
BUY for 101 days
PROFIT SINCE LAST BUY
+15.28% ▲
LAST CLOSE
$225.77
11/17/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for DHR

11/17/2026: DHR (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Danaher Corporation is a prominent science and technology enterprise operating in life sciences, diagnostics, and biotechnology. The company is well-regarded for its proprietary Danaher Business System, which drives operational efficiency and supports historically strong operating margins and recurring revenue streams. Its primary growth opportunity lies in capitalizing on secular trends in bioprocessing, genomic medicine, and clinical laboratory automation. However, investors must monitor risks related to biotech funding cyclicality, supply chain sensitivities, and a consistently premium equity valuation multiple. The stock is best suited for growth-oriented investors seeking exposure to high-quality healthcare technology with disciplined capital allocation.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitDanaher offers exposure to secular healthcare and bioprocessing growth trends backed by consistent innovation.
Momentum investorMixed fit while signal remains positiveMomentum fit depends heavily on prevailing sector sentiment and biotech funding cycles driving near-term price action.
Value investorMixed fitThe stock typically trades at a premium valuation reflecting its high-quality business model and execution history.
Dividend investorWeak fitWhile reliable, Danaher prioritizes capital reinvestment and M&A over high dividend yields.
Low-risk investorMixed fitResilient healthcare end-markets offer defensive qualities, though valuation multiples can introduce equity volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMediumBroader market corrections and shifts in healthcare sentiment can periodically trigger valuation multiple compression.
Valuation riskMedium / highThe company routinely trades at elevated price-to-earnings multiples relative to broader industrial peers.
Competition riskMediumAggressive market competition from major players like Thermo Fisher Scientific can challenge pricing power.
Business qualityStrongDanaher features high recurring revenue streams and a proven management operating system.
Dividend incomeLowIncome-focused investors will find the modest dividend yield secondary to capital appreciation goals.
Execution riskMediumSuccessful integration of large-scale acquisitions is critical to sustaining long-term compounding growth.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 161.75B USD
Price to earnings Ratio 38.06
1Y Target Price 259.9
Price to earnings Ratio 38.06
1Y Target Price 259.9
Volume (30-day avg) 4.1M shares
Beta 0.8
52 Weeks Range 160.31 - 241.35
Updated Date 11/17/2026
52 Weeks Range 160.31 - 241.35
Updated Date 11/17/2026
Dividends yield (FY) 0.65%
Basic EPS (TTM) 6.04

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
62.3%
Active BUY / eligible
66 / 106
30-Day BUY Count Change
+23
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Diagnostics & Research

BUY participation
53.8%
Active BUY / eligible
7 / 13
30-Day BUY Count Change
-2

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit -7.18%
Avg. Invested days 50
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/17/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
DHR receives a 4-star rating, supported by solid unit economics, solid company fundamentals, solid quantitative characteristics, and strong analyst coverage. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
DHR has solid overall fundamentals (4 stars), with solid financial health, moderate growth momentum, and strong ownership. In FY2025 versus FY2024, strong cash generation (FCF margin 21.4%) and solid profitability (net margin 14.7%) are partially offset by negative earnings growth (-7.3%), moderate revenue growth (+2.9%).

Financial Health Rating

★★★★★
DHR's financial health is supported by strong cash strength, including free-cash-flow generation of $5.3B (21.4% of revenue). Liquidity is moderate (3 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is DHR's strongest growth driver at +2.9% FY2025 versus FY2024 (moderate, 3 stars). By comparison, while earnings growth (-7.3%, negative) and free-cash-flow growth (-0.7%, slightly negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 85.5% and approximately 89.0% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 10.83% supports management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 7.83%
Vanguard Capital Management, LLC 5.88%
FMR Inc 4.20%
State Street Corp 4.04%
Capital Research & Mgmt Co - Division 3 2.58%

Unit Economics (Per $1K Revenue)

★★★★★
DHR generates approximately $609 of gross profit, $191 of operating income, and $214 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Solid margins and strong cash conversion support the rating, although capital efficiency remains soft.

Economic Dimensions

★★★★★
Effective Tax Rate: 14.95%

Quantitative Style Profile

★★★★★
DHR has a large-cap, liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Large / Mega Cap StabilityHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
BiotechnologyConsumables, filtration, and chromatography tools used to manufacture biologic medicines and vaccines.Generates steady recurring revenue as biotech drugs move through clinical trials to commercial production.
Life SciencesMass spectrometry systems, genomic research tools, and lab automation equipment.Provides essential equipment for academic and pharmaceutical research labs discovering new therapeutics.
DiagnosticsClinical laboratory instruments, molecular testing cartridges, and immunoassay reagents.Supplies hospitals and testing centers with diagnostic tests, benefiting from recurring test kit sales.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-10-21
When Before Market
Estimate 1.92
Actual 2.11

Profitability

Profit Margin 16.91%
Operating Margin (TTM) 21.97%

Management Effectiveness

Return on Assets (TTM) 4.06%
Return on Equity (TTM) 8.19%

Valuation

Trailing PE 38.06
Forward PE 24.88
Enterprise Value 182.55B
Price to Sales(TTM) 6.32
Enterprise Value 182.55B
Price to Sales(TTM) 6.32
Enterprise Value to Revenue 7.21
Enterprise Value to EBITDA 23.66
Shares Outstanding 703.53M
Shares Floating 626.35M
Shares Outstanding 703.53M
Shares Floating 626.35M
Percent Insiders 10.83
Percent Institutions 85.47

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.